Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice - PubMed (original) (raw)

Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice

A P Kuruvilla et al. Proc Natl Acad Sci U S A. 1991.

Abstract

Interleukin 1 (IL-1) and tumor necrosis factor alpha are thought to contribute to the inflammatory response associated with autoimmune diseases. Transforming growth factor beta 1 (TGF-beta 1) counteracts many effects of these cytokines and has various immunosuppressive properties. In the present study, it is shown that microgram amounts of TGF-beta 1, injected daily for 1-2 weeks, protect against collagen-induced arthritis (CIA) and relapsing experimental allergic encephalomyelitis (REAE), the animal models for rheumatoid arthritis and multiple sclerosis, respectively. When administered during induction of the disease, TGF-beta 1 prevents CIA but only delays the onset of REAE by 2-3 days. However, when administered during a remission. TGF-beta 1 prevents the occurrence of relapses in REAE. The results suggest that TGF-beta 1 has powerful anti-inflammatory effects, mimicking in some respects the beneficial effects of immunosuppressive drugs in these experimental models of autoimmune disease, but without discernable adverse effects.

PubMed Disclaimer

Similar articles

• Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10.
  Crisi GM, Santambrogio L, Hochwald GM, Smith SR, Carlino JA, Thorbecke GJ. Crisi GM, et al. Eur J Immunol. 1995 Nov;25(11):3035-40. doi: 10.1002/eji.1830251108. Eur J Immunol. 1995. PMID: 7489740
• Remission of collagen-induced arthritis is associated with high levels of transforming growth factor-beta expression in the joint.
  Marinova-Mutafchieva L, Gabay C, Funa K, Williams RO. Marinova-Mutafchieva L, et al. Clin Exp Immunol. 2006 Nov;146(2):287-93. doi: 10.1111/j.1365-2249.2006.03204.x. Clin Exp Immunol. 2006. PMID: 17034581 Free PMC article.
• Antagonistic effects of endogenous and exogenous TGF-beta and TNF on auto-immune diseases in mice.
  Santambrogio L, Hochwald GM, Leu CH, Thorbecke GJ. Santambrogio L, et al. Immunopharmacol Immunotoxicol. 1993 Aug;15(4):461-78. doi: 10.3109/08923979309035240. Immunopharmacol Immunotoxicol. 1993. PMID: 8227972
• Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor.
  Santambrogio L, Hochwald GM, Saxena B, Leu CH, Martz JE, Carlino JA, Ruddle NH, Palladino MA, Gold LI, Thorbecke GJ. Santambrogio L, et al. J Immunol. 1993 Jul 15;151(2):1116-27. J Immunol. 1993. PMID: 8335893
• TGF-beta as a promising option in the treatment of multiple sclerosis.
  Mirshafiey A, Mohsenzadegan M. Mirshafiey A, et al. Neuropharmacology. 2009 May-Jun;56(6-7):929-36. doi: 10.1016/j.neuropharm.2009.02.007. Epub 2009 Mar 11. Neuropharmacology. 2009. PMID: 19285095 Review.

Cited by

• TGF-β signaling in health, disease, and therapeutics.
  Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, He J. Deng Z, et al. Signal Transduct Target Ther. 2024 Mar 22;9(1):61. doi: 10.1038/s41392-024-01764-w. Signal Transduct Target Ther. 2024. PMID: 38514615 Free PMC article. Review.
• Transforming growth factor β (TGF-β) pathway in the immunopathogenesis of multiple sclerosis (MS); molecular approaches.
  Esmaeilzadeh A, Mohammadi V, Elahi R. Esmaeilzadeh A, et al. Mol Biol Rep. 2023 Jul;50(7):6121-6131. doi: 10.1007/s11033-023-08419-z. Epub 2023 May 19. Mol Biol Rep. 2023. PMID: 37204543 Review.
• Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.
  Barzaman K, Vafaei R, Samadi M, Kazemi MH, Hosseinzadeh A, Merikhian P, Moradi-Kalbolandi S, Eisavand MR, Dinvari H, Farahmand L. Barzaman K, et al. Cancer Cell Int. 2022 Aug 19;22(1):259. doi: 10.1186/s12935-022-02658-z. Cancer Cell Int. 2022. PMID: 35986321 Free PMC article. Review.
• Transforming growth factor-β1 protects against LPC-induced cognitive deficit by attenuating pyroptosis of microglia via NF-κB/ERK1/2 pathways.
  Xie Y, Chen X, Li Y, Chen S, Liu S, Yu Z, Wang W. Xie Y, et al. J Neuroinflammation. 2022 Jul 28;19(1):194. doi: 10.1186/s12974-022-02557-0. J Neuroinflammation. 2022. PMID: 35902863 Free PMC article.
• TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.
  Luo J. Luo J. Biomedicines. 2022 May 23;10(5):1206. doi: 10.3390/biomedicines10051206. Biomedicines. 2022. PMID: 35625943 Free PMC article. Review.

References

1. 1. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6 - PubMed
2. 1. J Clin Invest. 1990 May;85(5):1694-7 - PubMed
3. 1. N Engl J Med. 1987 Jan 8;316(2):67-72 - PubMed
4. 1. Clin Exp Immunol. 1986 Aug;65(2):293-302 - PubMed
5. 1. J Rheumatol. 1986 Oct;13(5):853-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations